Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR1H2 | P55055 | 1/20 | 0.45 |
| ▸ | PARP1 | P09874 | 1/20 | 0.41 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.41 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.41 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.41 |
| ▸ | USP2 | O75604 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | CTSK | P43235 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.38 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | MAPT | P10636 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
| ▸ | HPGD | P15428 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19616387 | 1.00 | NR1H2 (0.45) | NR1H2PARP1CHRM2CHRM1CHRM3 | |
| SCHEMBL30900005 | 0.93 | NR1H2 (0.47) | NR1H2PARP1CHRM2CHRM1CHRM3 | |
| SCHEMBL11993865 | 0.86 | NR1H2 (0.42) | NR1H2PARP1CHRM2CHRM1CHRM3 | |
| SCHEMBL15827357 | 0.86 | NR1H2 (0.42) | NR1H2PARP1CHRM2CHRM1CHRM3 | |
| SCHEMBL12240671 | 0.86 | NR1H2 (0.45) | NR1H2PARP1CHRM2CHRM1CHRM3 | |
| SCHEMBL1722772 | 0.86 | CYP1A2 (0.45) | NR1H2PARP1CHRM2CHRM1CHRM3 | |
| SCHEMBL20054277 | 0.86 | NR1H2 (0.42) | NR1H2PARP1CHRM2CHRM1CHRM3 | |
| SCHEMBL16080209 | 0.86 | NR1H2 (0.42) | NR1H2PARP1CHRM2CHRM1CHRM3 | |
| SCHEMBL20371652 | 0.86 | CYP1A2 (0.45) | NR1H2PARP1CHRM2CHRM1CHRM3 | |
| SCHEMBL16080242 | 0.86 | CYP1A2 (0.45) | NR1H2PARP1CHRM2CHRM1CHRM3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8367712-B2 | Substituted amide beta secretase inhibitors | Merck, Sharp & Dohme, Corp. (US) | 2013-02-05 | — | — | US | disclosed |
| US-8012953-B2 | Macrocyclic beta-secretase inhibitors | SCHERING CORPORATION (US) | 2011-09-06 | — | — | US | disclosed |
| US-20110003825-A1 | SUBSTITUTED AMIDE BETA SECRETASE INHIBITORS | SCHERING CORPORATION (US) | 2011-01-06 | — | — | US | disclosed |
| US-20100178294-A1 | MACROCYCLIC BETA-SECRETASE INHIBITORS | SCHERING CORPORATION | 2010-07-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100178294-A1 | MACROCYCLIC BETA-SECRETASE INHIBITORS | BACE1, BACE2, PSEN1 | NR1H2 21/4885PARP1 1538/4885CHRM2 115/4885 |
| US-20110003825-A1 | SUBSTITUTED AMIDE BETA SECRETASE INHIBITORS | BACE1, BACE2, SRR | NR1H2 21/4885PARP1 1915/4885CHRM2 96/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.